SequelSEC

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB

Laboratory Analytical Instruments · CIK 0001299130 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$159.27M
Fiscal year ended 2026-06-30
Operating income
-$133.04M
Fiscal year ended 2026-06-30
Free cash flow
-$123.42M
Fiscal year ended 2026-06-30

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) reported revenue of $159.27M and net income of -$131.39M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from PACIFIC BIOSCIENCES OF CALIFORNIA, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Laboratory Analytical Instruments.

Income

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$159.27M
Cost of revenue$101.32M
Gross profit$57.95M
Operating income-$133.04M
Net income-$131.39M
Research & development$88.36M
Weighted-average diluted sharesUnavailable
Pretax income-$130.56M
Income tax expense$827.00K
Diluted EPSUnavailable
Selling, general & administrative$129.70M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$61.00M
Total assets$751.85M
Current assets$338.64M
Total liabilities$785.06M
Current liabilities$68.81M
Total equity incl. NCI-$33.21M
Temporary (mezzanine) equityUnavailable
Inventory$61.08M
Accounts receivable$31.10M
Goodwill$317.76M
Long-term debtUnavailable
Accounts payable$19.22M

Cash flow

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$118.05M
Capital expenditures$5.37M
Investing cash flow$120.86M
Financing cash flow$3.16M
Net change in cash$5.97M
Stock-based compensation$34.29M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$123.42M
Gross margin36.4%
Operating margin-83.5%
FCF margin-77.5%
SBC / revenue21.5%
Current ratio4.92x
Revenue YoY growth2.0%
Net margin-82.5%
R&D / revenue55.5%
CapEx / revenue3.4%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PACB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-02-25View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

A ASTC AVTR BFNH BIO BNGO BRKR CTKB EYPT HBIO ILMN LCTC

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.